Axon Enterprise, Inc (NASDAQ:AXON) Shares Purchased by Sequoia Financial Advisors LLC

Sequoia Financial Advisors LLC lifted its position in Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 14.1% in the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 3,306 shares of the biotechnology company's stock after purchasing an additional 408 shares during the period. Sequoia Financial Advisors LLC's holdings in Axon Enterprise were worth $1,739,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in Axon Enterprise by 3.4% during the 4th quarter. Vanguard Group Inc. now owns 8,446,437 shares of the biotechnology company's stock worth $5,019,886,000 after acquiring an additional 275,959 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Axon Enterprise by 3.7% in the 4th quarter. Geode Capital Management LLC now owns 1,847,925 shares of the biotechnology company's stock worth $1,095,542,000 after purchasing an additional 65,097 shares during the period. Capital World Investors boosted its stake in shares of Axon Enterprise by 86.4% during the fourth quarter. Capital World Investors now owns 1,815,765 shares of the biotechnology company's stock valued at $1,079,145,000 after purchasing an additional 841,772 shares in the last quarter. Alliancebernstein L.P. boosted its stake in shares of Axon Enterprise by 273.8% during the fourth quarter. Alliancebernstein L.P. now owns 1,109,045 shares of the biotechnology company's stock valued at $659,128,000 after purchasing an additional 812,337 shares in the last quarter. Finally, Norges Bank purchased a new position in Axon Enterprise during the fourth quarter valued at approximately $482,081,000. Hedge funds and other institutional investors own 79.08% of the company's stock.

Insiders Place Their Bets

In other Axon Enterprise news, Director Michael Garnreiter sold 5,913 shares of the company's stock in a transaction on Wednesday, June 4th. The shares were sold at an average price of $760.00, for a total value of $4,493,880.00. Following the sale, the director directly owned 17,740 shares of the company's stock, valued at approximately $13,482,400. This represents a 25.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CRO Cameron Brooks sold 3,000 shares of Axon Enterprise stock in a transaction dated Friday, May 30th. The shares were sold at an average price of $740.76, for a total value of $2,222,280.00. Following the transaction, the executive owned 19,447 shares of the company's stock, valued at $14,405,559.72. The trade was a 13.36% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 44,642 shares of company stock worth $30,500,428. Company insiders own 5.70% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have issued reports on AXON. Needham & Company LLC lifted their target price on Axon Enterprise from $600.00 to $750.00 and gave the company a "buy" rating in a research note on Thursday, May 8th. Bank of America raised their price target on shares of Axon Enterprise from $750.00 to $895.00 and gave the company a "buy" rating in a report on Wednesday, June 4th. Barclays boosted their price objective on shares of Axon Enterprise from $726.00 to $735.00 and gave the stock an "overweight" rating in a research note on Friday, May 9th. The Goldman Sachs Group increased their target price on shares of Axon Enterprise from $730.00 to $830.00 and gave the company a "buy" rating in a research report on Wednesday, May 14th. Finally, Craig Hallum lowered shares of Axon Enterprise from a "buy" rating to a "cautious" rating in a report on Monday, March 10th. One analyst has rated the stock with a sell rating, one has issued a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, Axon Enterprise has a consensus rating of "Moderate Buy" and a consensus target price of $699.55.

Axon Enterprise Stock Performance

Axon Enterprise stock traded down $13.06 during trading hours on Tuesday, hitting $814.88. 83,218 shares of the stock traded hands, compared to its average volume of 706,141. The firm's 50 day moving average price is $720.69 and its 200-day moving average price is $631.70. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.83 and a quick ratio of 2.62. The stock has a market capitalization of $63.44 billion, a price-to-earnings ratio of 196.83, a P/E/G ratio of 94.23 and a beta of 1.29. Axon Enterprise, Inc has a 1 year low of $279.02 and a 1 year high of $830.21.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last released its earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 EPS for the quarter, topping analysts' consensus estimates of $1.34 by $0.07. Axon Enterprise had a return on equity of 5.81% and a net margin of 14.86%. The firm had revenue of $603.63 million during the quarter, compared to the consensus estimate of $585.67 million. During the same quarter in the previous year, the company posted $1.15 earnings per share. The company's revenue was up 31.3% compared to the same quarter last year. As a group, equities analysts expect that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.